GOSS Gossamer Bio, Inc.
Price Chart
Executive Summary
Gossamer Bio launched an exchange offer to swap up to $200M of 5.00% convertible notes due 2027 for $72M of new 7.50% secured notes due 2030, ~317.6M common shares, and up to 150M warrants, supported by holders of 75.2% of the existing notes via a transaction support agreement. The company also reported Q1 2026 financial results (revenue $17.0M, net loss -$46.7M), announced an FDA Pre-NDA Type B meeting for mid-June, and released positive exploratory CT FRI substudy results from the Phase 3 PROSERA trial. The exchange offer is the dominant event—it materially reduces debt but massively dilutes common equity, while the FDA meeting and imaging data provide a binary catalyst path.
Actionable Insight
The exchange offer's 98% minimum participation condition is the key near-term catalyst—if met, it eliminates near-term debt maturity risk but floods the float with shares. The FDA Pre-NDA meeting in mid-June is a binary event for seralutinib's regulatory path. Monitor the tender deadline (June 1 early tender, June 16 final) and the special meeting for stockholder approval of share authorization and reverse split. The PROSERA CT FRI data is supportive but exploratory; the FDA's view on a single-trial NDA is the real test.
Key Facts
- Exchange offer to swap up to $200M of 5.00% convertible notes due 2027 for $72M of new 7.50% secured notes due 2030, up to 317,647,058 common shares, and up to 150,000,000 warrants.
- Holders of 75.2% of existing notes have signed a transaction support agreement to tender; minimum participation condition of 98% of aggregate principal.
- Q1 2026 revenue from Chiesi collaboration was $17.0M (incl. $9.3M cost reimbursement), net loss -$46.7M ($0.20/share), cash $99.2M.
- FDA confirmed in-person Pre-NDA Type B meeting for mid-June 2026; NDA submission for seralutinib in PAH expected September 2026.
- PROSERA CT FRI substudy (n=162) showed statistically significant treatment effects across arterial, venous, and fibrosis parameters.
- Authorized shares to increase from 700M to 4B; reverse stock split range of 1:10 to 1:150 proposed.
- Estimated fees and expenses of ~$7.2M for the exchange offer.
Financial Impact
Debt reduction of $128M (from $200M to $72M) but massive dilution: up to 317.6M new shares + 150M warrants on a pre-offer share count of ~234M. Net loss widened to -$46.7M from -$36.6M YoY. Cash burn ~$37.7M in Q1.
Risk Factors
- Exchange offer may fail if <98% of noteholders tender, leaving the company with the full $200M debt maturity in 2027.
- Massive dilution from up to 317.6M new shares and 150M warrants could crush common stock price.
- FDA Pre-NDA meeting could result in a requirement for an additional trial, delaying or blocking NDA submission.
- Cash runway only into Q1 2027; further capital raises likely needed even if exchange offer closes.
- Reverse stock split (up to 1:150) signals potential Nasdaq delisting risk if share price remains low.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001728117-26-000037 |
| Document: 0001728117-26-000037-index-headers.html | 0001728117-26-000037 |
| Document: 0001728117-26-000037-index.html | 0001728117-26-000037 |
| Document: 0001728117-26-000037.txt | 0001728117-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $0.1554 awaiting T+1 | awaiting T+1 | — | $0.1620 (+4.25%) |
|
Jun 2, 2026
11d ago
|
8-K
| $0.2000 $0.1880 | ▼ −6.00% | ▼ −5.31% | $0.1620 (−19.00%) |
|
May 18, 2026
26d ago
|
DEFA14A
| $0.1930 $0.1990 | ▲ +3.11% | ▲ +3.76% | $0.1620 (−16.06%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $0.3490 $0.3450 | ▼ −1.15% | ▼ −0.66% | $0.1620 (−53.58%) |
|
Mar 19, 2026
12w ago
|
EFFECT
| $0.4520 $0.4220 | ▼ −6.64% | ▼ −4.90% | $0.1620 (−64.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access